Efficacy and Safety of Contezolid as an Alternative to Linezolid for Treating MRSA Spinal Infections Following Linezolid-Induced Thrombocytopenia: A Single-Center Retrospective Study

/L. Following transition to CZD (mean duration 66.6 ± 51.2 days; range 28-168), all patients achieved clinical success with no further platelet reduction. Platelet recovery to baseline or normal levels occurred within a mean of 8.25 ± 3.4 days (range 4-14). Three patients experienced gastrointestinal adverse events (nausea and vomiting), predominantly after the first dose. Our findings suggest that CZD may represent an effective and safe salvage therapy for patients with MRSA-SI who develop LZD-induced thrombocytopenia. Larger prospective studies are warranted to validate these preliminary findings.